Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:XPO
NYSE:XPOTransportation

Assessing XPO (XPO) Valuation After Service Improvements And Rising Hedge Fund Interest

Why XPO’s Recent Attention Is Catching Investor Interest Fresh commentary on XPO (XPO) centers on efforts to improve service quality, business mix, and pricing, alongside a rise in hedge fund ownership, which has drawn investors back to the freight carrier. See our latest analysis for XPO. The recent focus on service quality and mix comes as XPO’s share price return has been strong, with a 45.58% 3 month share price return and a very large 3 year total shareholder return. This suggests...
NasdaqGS:AGNC
NasdaqGS:AGNCMortgage REITs

How AGNC’s Reaffirmed US$0.12 Monthly Dividend Will Impact AGNC (AGNC) Investors

AGNC Investment Corp. previously announced that its Board of Directors declared a cash dividend of US$0.12 per common share for April 2026, payable on May 11, 2026 to shareholders of record as of April 30, 2026. This latest monthly dividend declaration underlines AGNC’s emphasis on recurring income for shareholders, supported by its large Agency mortgage-backed securities portfolio and focus on government-guaranteed assets. Next, we’ll explore how this reaffirmed US$0.12 monthly dividend...
NYSE:PIPR
NYSE:PIPRCapital Markets

A Look At Piper Sandler (PIPR) Valuation After 2025 Growth, Buybacks, Dividends And Stock Split

Why Piper Sandler Companies (PIPR) is in focus now Piper Sandler Companies (PIPR) is back on investor radars after reporting 2025 growth across advisory, equities institutional brokerage, public finance, and fixed income, along with a four-for-one stock split completed in March 2026. See our latest analysis for Piper Sandler Companies. The recent 1 month share price return of 18.27% and 7 day gain of 7.25% to US$83.47 contrast with a 90 day share price return of a 7.72% decline. At the same...
BME:SAN
BME:SANBanks

Banco Santander (BME:SAN) Is Up 7.2% After Major Buyback And Bond Issue Shift Capital Mix

In early April 2026, Banco Santander, S.A. completed several US dollar bond issues, including US$400 million of floating‑rate notes due 2029 and US$3.25 billion of fixed‑rate senior and non‑preferred notes maturing between 2029 and 2036, all issued at around par and featuring callable, unsecured, unsubordinated structures. Over roughly the same period, the bank disclosed that it has invested about €2.7 billion in an ongoing share buyback programme, retiring around 16.8% of its 2021 share...
NYSE:SITE
NYSE:SITETrade Distributors

Is SiteOne (SITE) Quietly Redefining Its M&A Playbook With Strategy Team Shake-Up And UBS Downgrade?

SiteOne Landscape Supply recently saw UBS reduce its analyst rating from "Buy" to "Neutral," while the company also announced upcoming first-quarter 2026 results and leadership changes in its strategy and development team. The elevation of Daniel Laughlin, a long-time corporate development leader with extensive M&A experience and RSU-based incentives, highlights how SiteOne is tying succession planning and growth initiatives closely to shareholder alignment. Next, we'll examine how UBS's...
NasdaqGS:ATAT
NasdaqGS:ATATHospitality

Earnings Beat And Easing Geopolitics Might Change The Case For Investing In Atour Lifestyle (ATAT)

In recent days, Atour Lifestyle Holdings reported a fourth-quarter earnings beat that pointed to stronger-than-expected business momentum, coinciding with easing geopolitical tensions after a U.S.-Iran ceasefire that supported travel and consumer names. An interesting aspect is how this combination of robust operating performance and lower oil-related macro risk has drawn in both fundamental and technically focused investors eyeing the company’s operating profile. We’ll now examine how this...
NYSE:RF
NYSE:RFBanks

A Look At Regions Financial (RF) Valuation As Optimism Builds Before Upcoming Earnings And Dividend Outlook

Regions Financial (RF) is back in focus as investors look ahead to its April 17 earnings release, with expectations for year-over-year growth in both revenue and earnings, as well as attention on its relatively high dividend yield. See our latest analysis for Regions Financial. Regions Financial’s share price has moved higher over the past month, with a 10% 30 day share price return, while the 1 year total shareholder return of 51.11% suggests investors have been rewarding the bank’s earnings...
NYSE:PRM
NYSE:PRMChemicals

Assessing Perimeter Solutions (PRM) Valuation After Sales Growth Momentum And Medical Manufacturing Technologies Deal

Why Perimeter Solutions (PRM) Is Back on Investor Radars Perimeter Solutions (PRM) has drawn fresh attention after reporting 2025 sales growth of 16% and spotlighting momentum in its specialty products segment, alongside a US$685 million purchase of Medical Manufacturing Technologies. See our latest analysis for Perimeter Solutions. The share price has moved higher over the past month, with a 1 month share price return of 11.95%. However, the year to date share price return of 7.38% and 90...
NasdaqGS:ASTS
NasdaqGS:ASTSTelecom

A Look At AST SpaceMobile (ASTS) Valuation After Revenue Surge And BlueBird Contract Wins

AST SpaceMobile (ASTS) reported very large year over year revenue growth to US$70.9 million in the fourth quarter of 2025. The company also updated investors on its commercial satellite launch timeline and BlueBird constellation rollout targets. See our latest analysis for AST SpaceMobile. The latest quarterly update, including very large revenue growth and a clearer satellite rollout schedule, comes after a 9.91% 1 month share price return and a 13.69% year to date share price return. The 1...
NYSE:MRK
NYSE:MRKPharmaceuticals

Does New KEYTRUDA EU Ovarian Cancer Approval Reshape The Bull Case For Merck (MRK)?

Earlier this month, Merck announced positive Phase 3 data for its investigational oral PCSK9 inhibitor enlicitide and secured European Union approval for KEYTRUDA in combination with paclitaxel, with or without bevacizumab, for certain adults with platinum-resistant ovarian, fallopian tube or primary peritoneal carcinoma whose tumors express PD-L1. These developments extend Merck’s reach in both cardiovascular and oncology care, potentially diversifying its product mix as it prepares for...
NasdaqGS:SNEX
NasdaqGS:SNEXCapital Markets

A Look At StoneX Group (SNEX) Valuation After New Pathfinder Payments Partnership

StoneX Group (SNEX) recently announced a partnership with The Pathfinder Group to plug its global payments infrastructure into Pathfinder’s WITS wire platform, giving more financial institutions access to institutional-grade cross-border payments. See our latest analysis for StoneX Group. The partnership news comes after a strong run in the shares, with a 34.6% 30 day share price return and a 43.1% year to date share price return, while the 5 year total shareholder return of 375.1% points to...
NYSE:TME
NYSE:TMEEntertainment

Tencent Music Entertainment Group (NYSE:TME) Valuation Check As Options Volatility Climbs And Analyst Caution Grows

Recent trading in Tencent Music Entertainment Group (NYSE:TME) options has shown unusually high implied volatility. This points to expectations of sharp share price swings, while analyst sentiment on the stock and sector remains cautious. See our latest analysis for Tencent Music Entertainment Group. The latest share price of $9.36 sits against a 30 day share price return of 34.04% and a year to date share price return of 47.59%, while the 1 year total shareholder return of 21.48% contrasts...
NYSE:BR
NYSE:BRProfessional Services

A Look At Broadridge Financial Solutions (BR) Valuation After New Digital Asset And Tokenization Milestones

Broadridge Financial Solutions (BR) has moved deeper into digital assets, extending its governance platform to cover tokenized securities and reporting very large Distributed Ledger Repo volumes, which puts its blockchain based post trade capabilities in sharper investor focus. See our latest analysis for Broadridge Financial Solutions. Despite strong recent news around digital assets and an earnings beat, Broadridge’s 30 day share price return of 15.25% and year to date share price return of...
TSX:WSP
TSX:WSPConstruction

Assessing WSP Global (TSX:WSP) Valuation After Fresh Attention From Investment Expert Commentary

Why WSP Global is Back on Investors’ Radar Recent commentary from Brian Madden, chief investment officer at First Avenue Investment Counsel, has put WSP Global (TSX:WSP) back in focus for many investors, highlighting its business outlook and investment potential. See our latest analysis for WSP Global. Despite the recent attention, WSP Global’s share price has softened in the short term, with a 90 day share price return of a 17.7% decline and a year to date share price return of a 12.5%...
ASX:TPG
ASX:TPGTelecom

How Soul Patts’ Exit and Board Change At TPG Telecom (ASX:TPG) Has Changed Its Investment Story

Washington H. Soul Pattinson and related entities recently sold 61.5 million TPG Telecom shares for about A$245 million and ceased to be substantial shareholders, while long-time representative Robert Millner retired from the TPG board following the May 2026 AGM. This combination of ownership exit and board change reshapes TPG Telecom’s long-term shareholder mix and governance links to a formerly influential investor. Next, we’ll examine how Soul Patts’ exit from the register may influence...
NasdaqGS:VIR
NasdaqGS:VIRBiotechs

Should Vir’s CMO Exit and Astellas Funding Boost Reshape How Investors View Its R&D Strategy (VIR)?

In April 2026, Vir Biotechnology announced that Executive Vice President and Chief Medical Officer Mark Eisner will step down on April 24, 2026, while the company continues advancing its Bispecific T-Cell engager programs in oncology and infectious diseases. At the same time, Vir’s recently completed collaboration with Astellas, built on positive Phase 1 prostate cancer data, has strengthened its funding base for upcoming clinical trials and highlighted the importance of effective leadership...
OB:VEI
OB:VEIConstruction

Veidekke (OB:VEI) Valuation Check After Record Oslofjord Road Contract Wins Investor Attention

Why Veidekke’s latest road contract is on investors’ radar Veidekke (OB:VEI) has secured a design and build contract for the second phase of the E134 Oslofjord Connection, the largest agreement in the company’s history. It is set to enter the order backlog in Q2 2026. See our latest analysis for Veidekke. Veidekke’s NOK197.0 share price comes after a 9.2% 90 day share price return and a 12.44% year to date share price return. The 1 year total shareholder return of 45.52% points to firm...
NYSE:CL
NYSE:CLHousehold Products

A Look At Colgate-Palmolive’s Valuation As Mixed Recent Returns Meet A 12.8% Undervaluation Estimate

Colgate-Palmolive triggered stock overview Colgate-Palmolive (CL) has recently come into focus as investors reassess consumer staples after mixed share performance over the past year, with the stock closing at US$84.34 and longer term returns varying by timeframe. See our latest analysis for Colgate-Palmolive. Recent trading has been choppy, with a 1 day share price return of a 2.0% decline and a 30 day share price return of a 5.1% decline. However, year to date the share price return is 8.6%...
NYSE:RJF
NYSE:RJFCapital Markets

Is Cautious Analyst Stance and Insider Selling Altering The Investment Case For Raymond James Financial (RJF)?

In recent days, several major Wall Street firms, including Goldman Sachs, Morgan Stanley, UBS, TD Cowen, Barclays, and Jefferies, reiterated ratings on Raymond James Financial while resetting their views on the company. At the same time, increased insider selling by senior executives has added a layer of caution to how the market interprets Raymond James Financial’s near-term prospects. Next, we’ll examine how this wave of cautious analyst ratings and insider selling may influence Raymond...
NYSE:INSW
NYSE:INSWOil and Gas

How Extending Its Poison Pill and Raising the Trigger Price At International Seaways (INSW) Has Changed Its Investment Story

In early April 2026, International Seaways extended its shareholder rights plan to April 8, 2029 and lifted the plan’s purchase price to US$95, reinforcing protections against unsolicited takeover efforts. This move tightens control over potential ownership changes and could meaningfully influence how International Seaways balances capital allocation, corporate control, and long-term governance priorities. We’ll now examine how extending the shareholder rights plan to 2029 could influence...